Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Gilead Sciences Inc (GILD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 93,777,232
  • Shares Outstanding, K 1,296,340
  • Annual Sales, $ 26,107 M
  • Annual Income, $ 4,628 M
  • 36-Month Beta 1.01
  • Price/Sales 3.64
  • Price/Cash Flow 7.61
  • Price/Book 4.37

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 20 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate 1.56
  • Number of Estimates 8
  • High Estimate 1.71
  • Low Estimate 1.45
  • Prior Year 2.23
  • Growth Rate Est. (year over year) -30.04%

Price Performance

See More
Period Period Low Period High Performance
1-Month
71.17 +0.01%
on 10/23/18
79.61 -10.59%
on 10/03/18
-4.33 (-5.73%)
since 09/21/18
3-Month
71.17 +0.01%
on 10/23/18
79.61 -10.59%
on 10/03/18
-6.20 (-8.01%)
since 07/23/18
52-Week
64.27 +10.75%
on 05/03/18
89.54 -20.50%
on 01/29/18
-8.99 (-11.21%)
since 10/23/17

Most Recent Stories

More News
The Zacks Analyst Blog Highlights: Roche, Gilead and Bristol Myers

The Zacks Analyst Blog Highlights: Roche, Gilead and Bristol Myers

GILD : 71.09 (-1.73%)
RHHBY : 30.5000 (-0.68%)
BMY : 50.01 (-1.71%)
Will Gilead (GILD) HIV Sales Offset HCV Sales Decline in Q3?

Gilead Sciences (GILD) is scheduled to report third-quarter results on Oct 25. We expect investors to focus on the strong HIV franchise and other pipeline updates.

GILD : 71.09 (-1.73%)
REGN : 378.56 (-2.38%)
GLPG : 104.41 (-3.23%)
AMGN : 194.72 (-1.67%)
Positive Trial Results with Filgotinib in Psoriatic Arthritis and Ankylosing Spondylitis Both Published in The Lancet

Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that detailed results from two clinical trials evaluating filgotinib, an investigational, selective...

GILD : 71.09 (-1.73%)
GLPG : 104.41 (-3.23%)
Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know

In the latest trading session, Gilead Sciences (GILD) closed at $74.17, marking a -1.92% move from the previous day.

GILD : 71.09 (-1.73%)
AELIX Therapeutics and Gilead Sciences Enter into a Clinical Research Collaboration Agreement to Evaluate a Therapeutic Vaccine and TLR7 Agonist Regimen for HIV Cure

AELIX Therapeutics S.L. ("AELIX"), a clinical-stage biotechnology company specialized in the discovery and development of immunotherapies for HIV infection, today announces that it has entered...

GILD : 71.09 (-1.73%)
Akero Therapeutics Expands Leadership Team

Akero Therapeutics, Inc., a biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases, today announced the appointment of...

GILD : 71.09 (-1.73%)
Gilead Sciences Rises 3.52% on Heavy Volume: Watch For Potential Pullback

Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $73.04 to a high of $75.54. Yesterday, the shares gained 3.5%, which took the trading range above the 3-day high of...

GILD : 71.09 (-1.73%)
Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, Gilead Sciences (GILD) closed at $73.59, marking a +1.5% move from the previous day.

GILD : 71.09 (-1.73%)
Gilead Sciences to Release Third Quarter 2018 Financial Results on Thursday, October 25, 2018

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its third quarter 2018 financial results will be released on Thursday, October 25, after the market closes. At 4:30 p.m. Eastern...

GILD : 71.09 (-1.73%)
Gilead Sciences Set to Possibly Rebound After Yesterday's Selloff of 1.10%

Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $73.03 to a high of $75.19. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $74.75...

GILD : 71.09 (-1.73%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators mostly agree with the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade GILD with:

Business Summary

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The Company strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead's portfolio of products...

See More

Key Turning Points

2nd Resistance Point 74.26
1st Resistance Point 73.30
Last Price 71.09
1st Support Level 71.78
2nd Support Level 71.22

See More

52-Week High 89.54
Fibonacci 61.8% 79.89
Fibonacci 50% 76.90
Fibonacci 38.2% 73.92
Last Price 71.09
52-Week Low 64.27

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar